ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $21.00 to $22.00. They now have an "overweight" rating on the stock.
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at Guggenheim.
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.